Frontlight ResearchEarly access
CompletedNo phase
Clinical Study Evaluating the Efficacy and Safety of Colchicine in Adult Patients With Sepsis
Key facts
- Who runs it
- Tanta University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 46 people enrolled
- Started
- 1 Nov 2023
- Ended
- 30 Aug 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- conventional sepsis therapy alone
- colchicine 500 mcg oral twice daily plus conventional sepsis therapy.
- Record updated
- 23 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Other criteria
- Inclusion criteria:; Adult age ≥18 years old; Both male and female sex; Patients diagnosed with sepsis regardless its etiology according to the definitions of SSC
- Exclusion criteria:; Late septic shock at presentation with multiple organ failure; Serious gastrointestinal disease; Preexisting end stage liver disease; Preexisting end stage renal disease; Pregnancy and breast-feeding women; History of allergy or intolerance to Colchicine; Patient with malignancies; Uncontrolled hemorrhage; Burn; Patients on immunosuppressant or biological therapies; Concomitant use of P-glycoprotein (P-gp) inhibitor such as: Verapamil, and Amiodarone or strong CYP3A4 inhibitor such as: Clarithromycin, Ritonavir and Ketoconazole
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Inflammatory markers are found to be an important contributor in sepsis. We evaluate the effect of colchicine on inflammatory processes and its possible protective effect against oxidative stress and organ dysfunction in adult patients suffering from sepsis.
The 2 groups in the trial
- Group 1 (Control group)Placebo, for comparison
Treatment: conventional sepsis therapy alone
- Group 2 (Colchicine group)Existing treatment, for comparison
Treatment: colchicine 500 mcg oral twice daily plus conventional sepsis therapy.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Study Evaluating the Efficacy and Safety of Colchicine in Adult Patients With Sepsis.
- Record updated
- 23 July 2025